FHTX
NASDAQFoghorn Therapeutics Inc.
Price$1.86+0.03 (+1.64%)
01:30 PM07:45 PM
News · 26 weeks35+100%
2026-04-192026-10-11
Mix1190d
- Analyst4(36%)
- Other3(27%)
- SEC Filings3(27%)
- Insider1(9%)
Latest news
25 items- ANALYSTFoghorn Therapeutics downgraded by Evercore ISI with a new price targetEvercore ISI downgraded Foghorn Therapeutics from Outperform to In-line and set a new price target of $3.00
- INSIDERSEC Form 3 filed by Foghorn Therapeutics Inc.3 - Foghorn Therapeutics Inc. (0001822462) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Foghorn Therapeutics Inc.SCHEDULE 13G/A - Foghorn Therapeutics Inc. (0001822462) (Subject)
- ANALYSTFoghorn Therapeutics downgraded by BTIG ResearchBTIG Research downgraded Foghorn Therapeutics from Buy to Neutral
- ANALYSTFoghorn Therapeutics downgraded by TD CowenTD Cowen downgraded Foghorn Therapeutics from Buy to Hold
- ANALYSTFoghorn Therapeutics downgraded by Wedbush with a new price targetWedbush downgraded Foghorn Therapeutics from Outperform to Neutral and set a new price target of $2.00
- SECFoghorn Therapeutics Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Foghorn Therapeutics Inc. (0001822462) (Filer)
- PRFoghorn Therapeutics Provides Update on FHD-909 and Strategic PrioritiesFoghorn and Lilly will not advance FHD-909; The Collaboration also will not advance the Selective SMARCA2 degrader programCompany to focus resources on wholly owned pipeline, including a Selective EP300 degrader, a novel, oral immunology and inflammation program, a Selective CBP degrader and induced proximity platformPipeline prioritization and organizational changes expected to extend cash runway into the second half of 2029, including an approximately 40% workforce reduction WATERTOWN, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a biotechnology company pioneering a new class of medicines that treat serious diseases, today announced that, following
- SECSEC Form 10-Q filed by Foghorn Therapeutics Inc.10-Q - Foghorn Therapeutics Inc. (0001822462) (Filer)
- SECFoghorn Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Foghorn Therapeutics Inc. (0001822462) (Filer)
- PRFoghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update- FHD-909 (LY4050784) Phase 1 dose-escalation trial advancing as planned with non-small cell lung cancer (NSCLC) as the primary target population - Selective EP300 degraders with potential to treat multiple myeloma and other hematological malignancies advancing; IND targeted in 2027 - Accelerating a novel oral small molecule in immunology and inflammation toward IND in 2027 - Strong balance sheet with cash, cash equivalents, and marketable securities of approximately $168 million; cash runway into the first half of 2028 WATERTOWN, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicine
- PRStep Pharma announces the appointment of Neil Gallagher as Non-Executive DirectorNeil Gallagher, MD, PhD, joins with over 25 years clinical development experience, having contributed to multiple commercial therapeutics across haematology and oncologyHis appointment will strengthen Step Pharma’s board as it advances dencatistat across three clinical programmes for essential thrombocythaemia (ET), lymphoma and solid tumours. Saint-Genis-Pouilly, France, 1 July 2026 – Step Pharma ("the Company"), the global leader in CTPS1 inhibition for targeted cancer treatment, today announces the appointment of Neil J. Gallagher, MD, PhD, as Non-Executive Director effective immediately. He will support the Company as it continues to advance its first-in-class CTPS1 inhibitor, dencatis
- INSIDERSEC Form 4 filed by Director Lynch Thomas J. Jr.4 - Foghorn Therapeutics Inc. (0001822462) (Issuer)
- INSIDERSEC Form 4 filed by Director Duty Stuart4 - Foghorn Therapeutics Inc. (0001822462) (Issuer)
- INSIDERSEC Form 4 filed by Director Biller Scott4 - Foghorn Therapeutics Inc. (0001822462) (Issuer)
- INSIDERSEC Form 4 filed by Director Gallagher Neil4 - Foghorn Therapeutics Inc. (0001822462) (Issuer)
- INSIDERSEC Form 4 filed by Director Mendelsohn Michael4 - Foghorn Therapeutics Inc. (0001822462) (Issuer)
- INSIDERSEC Form 4 filed by Director Smith Ian F4 - Foghorn Therapeutics Inc. (0001822462) (Issuer)
- INSIDERSEC Form 4 filed by Director Gill Simba4 - Foghorn Therapeutics Inc. (0001822462) (Issuer)
- INSIDERSEC Form 4 filed by Director Parshall B Lynne4 - Foghorn Therapeutics Inc. (0001822462) (Issuer)
- INSIDERSEC Form 4 filed by Director Cole Douglas G.4 - Foghorn Therapeutics Inc. (0001822462) (Issuer)
- SECFoghorn Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Foghorn Therapeutics Inc. (0001822462) (Filer)
- PRNext-Generation DNA Repair Therapies Open New Frontiers in OncologyAUSTIN, Texas, June 22, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors, which work by blocking cancer cells’ ability to repair their own damaged DNA, is expanding rapidly beyond its original anchor, the PARP inhibitor. DDRi therapies collectively represented an estimated $7-plus billion in global sales in 2025, and the broader oncology, diagnostics and precision medicine markets are projected to climb to roughly $750 billion by 2030. New inhibitor classes are emerging as the next major wave. Sitting at the forefront of this shift is Onco-Innovations Li
- PRFoghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026WATERTOWN, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026. With an initial focus in oncology, Foghorn's Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases. Goldman Sachs 47th Annual Global Healthcare Conference 2026 Fireside Chat: Tuesday, June 9, 2026, at 1:20 p.m. EDTPresenter: Adrian Gottschal
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Foghorn Therapeutics Inc.SCHEDULE 13G/A - Foghorn Therapeutics Inc. (0001822462) (Subject)
FHTX FAQ
7 questionsWhat does Foghorn Therapeutics Inc. do?
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia; and FHD-609, a small molecule protein degrader of BRD9 to treat patients with...Where does FHTX stock trade?
Foghorn Therapeutics Inc. (FHTX) is listed on NASDAQ.What sector and industry is FHTX in?
Foghorn Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Foghorn Therapeutics Inc. go public?
Foghorn Therapeutics Inc. (FHTX) completed its IPO in 2020.What are analysts saying about FHTX?
Foghorn Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Evercore ISI: In-line with a $300.00 price target on 2026-10-13.What companies are similar to FHTX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare FHTX side-by-side with any of them on Quantisnow.How can I track FHTX on Quantisnow?
Quantisnow aggregates Foghorn Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow FHTX to receive live email and push alerts on every new disclosure.